IMW 2019 | Updated FDA MRD guidelines for hematological malignancies

Nicole Gormley

Nicole Gormley, MD, FDA, Silver Spring, MD, discusses the updated measurable residual disease (MRD) guidlines being produced by the FDA at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

Share this video  
Similar topics